

- 2003- 2005 *Stanley Foundation* (USA; grant # 02T-229). The effect of add-on oral dehydroepiandrosterone to stable ongoing antipsychotic treatment in schizophrenia patients. A randomized double-blind placebo-controlled, crossover trial. PI – M. Ritsner, Co-PI – R. Strous
- 2003- 2006 Pfizer Pharmaceuticals Israel Ltd. Quality of life outcomes with antipsychotic treatment of schizophrenia patients: a one year prospective naturalistic comparative study of ziprasidone with atypical and typical antipsychotic agents. PI – M. Ritsner
- 2005 - 2006 *Stanley Foundation* (USA; grant # 05T-648). Safety and efficacy of add-on oral of add-on oral bexarotene to antipsychotic treatment in schizophrenia patients: an open label. PI - V. Lerner, Co-PI - M. Ritsner.
- 2006 - 2008 *Stanley Foundation* (USA; grant #06TGF-911). The value of augmenting L-Theanine in the management of schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. PI - M. Ritsner.
- 2007- *Stanley Foundation* (USA; grant #07TGF-1097). Bexarotene as addition to antipsychotic treatment in schizophrenia patients: double-blind placebo controlled study. PI - V. Lerner, Co-PI - M. Ritsner.
- 2008 - 2010 *Stanley Foundation* (USA; grant #08TGF-1189). Pregnenolone Augmentation in the Treatment of Patients with Recent-Onset Schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. PI - M. Ritsner, Co-PI - A. Kreinin.

Publications (2005-2011):

1. Kurs, R., Farkas, H., Ritsner, M. Quality of life and temperament factors in schizophrenia: Comparative study of patients, their siblings and controls. Quality of Life Research 14:433-440 (2005).
2. Strous, RD, Ratner, Y, Gibel, A, Ponizovsky, A, Ritsner, M. Longitudinal assessment of coping abilities at exacerbation and stabilization in schizophrenia. Compr Psychiatry 46:167-175 (2005).
3. Ritsner M, Kurs R, Ratner Y, Gibel A. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Res. 135:65-75 (2005).
4. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005; 14:1693-1703.

5. Ritsner M, Gibel A, Maayan R, Ratner Y, Ram E, Biadsy H, Modai I, Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology. 2005; 30:1913-1922.
6. Ritsner M, Ratner Y, Gibel A, Weizman R. Familiality in a five-factor model of schizophrenia psychopathology: findings from a 16-month follow-up study. Psychiatry Res. 2005; 136:173-179.
7. Ritsner MS, Blumenkrantz H, Dubinsky T, Dwolatzky T. The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophrenia Res. 2006; 82:39-49.
8. Ritsner M, Gibel A, Ram E, Maayan R, Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur Neuropsychopharmacol. 2006; 16:137-146.
9. Ritsner M, Gibel A, Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Qual Life Res. 2006; 15:515-526.
10. Ritsner MS, Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006; 30:1442–1452.
11. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol. 2006; 26:495-499.
12. Ponizovsky AM, Grinshpoon A, Pugachev I, Nahon D, Ritsner M, Abramowitz MZ. Changes in stability of first-admission psychiatric diagnoses over 14 years, based on cross-sectional data at three time points. Isr J Psychiatry Relat Sci. 2006; 43:34-39.
13. Ritsner M, Ratner Y. The long-term changes in coping strategies in schizophrenia: Temporal coping types. J Nerv Ment Dis. 2006; 194:261-267.
14. Ritsner MS, Gibel A, Ponizovsky AM, Shinkarenko E, Ratner Y, Kurs R. Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patients. Psychiatry Res. 2006 Nov 15;144(2-3):139-52.
15. Ritsner MS, Ratner Y, Gibel A, Weizman R. Positive family history is associated with persistent elevated emotional distress in schizophrenia: Evidence from a 16-month follow-up study. Psychiatry Res. 2007;153:217-23.
16. Ratner Y, Gibel A, Yorkov V, Ritsner MS. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1401-9.
17. Ritsner MS, Yorkov V, Ratner Y, Soifer P, Gibel A. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:1470-7.
18. Ritsner MS. Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Qual Life Res. 2007; 16:929-37.

19. Ritsner MS, Blumenkrantz H. Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits. *Psychiatry Res.* 2007;149:59-69.
20. Ritsner M, Maayan R, Gibel A, Weizman A. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. *Eur Neuropsychopharmacol.* 2007; 17:358-65.
21. Ritsner M, Gibel A, Maayan R, Ratner Y, Ram E, Modai I, Weizman A. State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. *Eur Neuropsychopharmacol.* 2007; 17:257-64.
22. Gibel A, Ritsner MS. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. *Clin Neuropharmacol.* 2008; 31(4): 204-220.
23. Strous RD, Gibel A, Maayan R, Weizman A, Ritsner MS. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study. *J Clin Psychopharmacol.* 2008; 28(4): 456-459.
24. Lerner V, Miodownik C, Gibel A, Kovalyonok E, Shleifer T, Goodman AB, Ritsner MS. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. *Clin Neuropharmacol.* 2008; 31(1):25-33.
25. Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, Lachman H, Weizman A. Improvement of aggressive behavior and quality of life impairment following S-Adenosyl-Methionine (SAM-e) augmentation in schizophrenia. *Eur Neuropsychopharmacol.* 2009;19(1):14-22.
26. Ritsner MS, Strous RD. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. *J Psychiatr Res.* 2010;44(2):75-80.
27. Ritsner, MS, Gibel, A, Shleifer, T, Boguslavsky, I, Zayed, A, Maayan, R, Weizman, A, Lerner, V. Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia: An 8-week, Double-Blind, Randomized, Controlled, Two-Center, Parallel-Group Trial. *J Clin Psychiatry*, 2010;71(10):1351-1362.
28. Ritsner MS, Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., Lerner, V. L-Theanine Relieves Positive, Activation, and Anxiety Symptoms in Patients with Schizophrenia and Schizoaffective Disorders: An 8-week, Randomized, Double-Blind, Placebo-Controlled, Two-Center Study. *J Clin Psychiatry*, 2010 Nov 30. [Epub ahead of print] PubMed PMID: 21208586.
29. Ritsner MS, Arbitman M, Lisker A. Anhedonia Is an Important Factor of Health-Related Quality-of-Life Deficit in Schizophrenia and Schizoaffective Disorder. *J Nerv Ment Dis.* 2011 Nov;199(11):845-53. PubMed PMID: 22048136.
30. Ritsner MS, Arbitman M, Lisker A, Ponizovsky AM. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. *Qual Life Res.* 2011 Oct 2. [Epub ahead of print] PubMed PMID: 21964946.
31. Ritsner MS, Lisker A, Arbitman M. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. *Qual Life Res.* 2011 Sep 13. [Epub ahead of print]

Books

1. Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. New Perspectives on Research and Treatment. Ritsner, Michael S.; Awad, A. George (Eds.), Springer-Verlag New York, 2007, 388 p. ISBN: 978-1-4020-5777-9.
2. Neuroactive Steroids in Brain Functions, and Mental Health. New Perspectives for Research and Treatment. Ritsner, Michael S.; Weizman A. (Eds.), Springer-Verlag New York, 2008.
3. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes, and Genes. *Volumes I-IV*. Ritsner, Michael S. (Ed.), Springer-Verlag New York. 2009.
4. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner, Michael S. (Ed.), Springer-Verlag New York. 2010. 663 p.

Book chapters

5. Ritsner MS. The Distress/Protection Vulnerability Model of the quality of life impairment syndrome: current evidence and new directions for research. In: Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. New Perspectives on Research and Treatment. Ritsner, Michael S.; Awad, A. George (Eds.), Springer, 2007, 3-19.
6. Ritsner MS. Comparison of instruments for measuring quality of life impairment syndrome in severe mental disorders: Q-LES-Q versus QLS and LQOLP. In: Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. New Perspectives on Research and Treatment. Ritsner, Michael S.; Awad, A. George (Eds.), Springer, 2007, 133-142.
7. Ritsner MS, Gibel A. Quality of life impairment syndrome in schizophrenia. Ritsner, Michael S.; Awad, A. George (Eds.), Springer, 2007, 173-226.
8. Ritsner MS, Gibel A, Ratner Y, Weizman A. Dehydroepiandrosterone and Pregnenolone Alterations in Schizophrenia. In: Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders. Novel Strategies for Research and Treatment. Michael S. Ritsner, and Abraham Weizman, Editors. Springer, pp.251-298. 2008.
9. Ritsner MS. Dehydroepiandrosterone Administration in Treating Medical and Neuropsychiatric Disorders: High Hopes, Disappointing Results, and Topics for Future Research. In: Neuroactive Steroids in Brain Function, Behavior and

Neuropsychiatric Disorders. Novel Strategies for Research and Treatment.
Michael S. Ritsner, and Abraham Weizman, Editors. Springer, pp.337-368. 2008.

10. Ritsner, M., and Kurs, R. Quality-of-life impairment in severe mental illness: focus on schizoaffective disorders. In: Schizoaffective Disorder: New Research. Ed. William H. Murray, NOVA Publishers, NY, Chapter 3, pp. 69-107. 2009.
11. Ritsner MS, Gottesman II. Where do we stand in the quest for neuropsychiatric biomarkers and endophenotypes and what next? The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes Edited by Michael S. Ritsner. Springer, Vol I, pp. 3-21, 2009.
12. Gallagher P., Ritsner MS. Can the cortisol to DHEA molar ratio be used as a peripheral biomarker for schizophrenia and mood disorders? The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes Edited by Michael S. Ritsner. Springer, Vol III, pp. 27-45, 2009.
13. Ritsner MS, Susser E. Molecular genetics of schizophrenia: focus on symptom dimensions. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes Edited by Michael S. Ritsner. Springer, Vol IV, pp. 95-124, 2009.
14. Ehud Susser E, Ritsner MS. Brain protection in neuropsychiatric disorders: Past, present and future challenges. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner, Michael S. (Ed.), Springer-Verlag New York. 2010. pp. 3-25.
15. Ritsner MS. Is a Neuroprotective Therapy Suitable for Schizophrenia Patients? Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner, Michael S. (Ed.), Springer-Verlag New York. 2010. pp. 343-395.